PET Imaging of Breast Cancer: Role in Patient Management.

Breast cancer is the most common malignancy in females. Imaging plays a critical role in diagnosis, staging and surveillance, and management of disease. Fluorodeoxyglucose (FDG) PET the imaging is indicated in specific clinical setting. Sensitivity of detection depends on tumor histology and size. Whole body FDG PET can change staging and management. In recurrent disease, distant metastasis can be detected. FDG PET imaging has prognostic and predictive value. PET/MR is evolving rapidly and may play a role management, assessment of metastatic lesions, and treatment monitoring. This review discusses current PET modalities, focusing on of FDG PET imaging and novel tracers.

[1]  R. Hustinx,et al.  Sequential Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Response to Chemotherapy in Metastatic Breast Cancer , 2006, Clinical Cancer Research.

[2]  M. Marzola,et al.  Lobular breast carcinoma: a case of rare possible 18F-FDG PET/CT and bone scan false negative. , 2015, Clinical nuclear medicine.

[3]  David A. Mankoff,et al.  Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol , 2008, Journal of Nuclear Medicine.

[4]  Yongxue Zhang,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis. , 2013, Clinical breast cancer.

[5]  J. Bonneterre,et al.  Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course. , 2010 .

[6]  C. Dence,et al.  Small-Animal PET of Steroid Hormone Receptors Predicts Tumor Response to Endocrine Therapy Using a Preclinical Model of Breast Cancer , 2012, The Journal of Nuclear Medicine.

[7]  M. Alvarez,et al.  Disseminated osteomyelitis or bone metastases of breast cancer: 18F-FDG-PET/CT helps unravel an unusual presentation , 2014, Annals of Nuclear Medicine.

[8]  C. Coutant,et al.  Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using 18F-FDG PET in luminal HER2-negative breast cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  R L Wahl,et al.  Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  M. Mintun,et al.  Breast cancer: PET imaging of estrogen receptors. , 1988, Radiology.

[11]  R. Staff,et al.  The use of FDG-PET in assessing axillary lymph node status in breast cancer: a systematic review and meta-analysis of the literature , 2010, Breast Cancer Research and Treatment.

[12]  Paul Kinahan,et al.  Clinical Imaging Characteristics of the Positron Emission Mammography Camera: PEM Flex Solo II , 2009, Journal of Nuclear Medicine.

[13]  M. Serin,et al.  False Positive 18F-FDG Uptake in Mediastinal Lymph Nodes Detected with Positron Emission Tomography in Breast Cancer: A Case Report , 2013, Case reports in medicine.

[14]  A. Bhattacharya,et al.  Role of 18F-FDG PET/CT in identifying distant metastatic disease missed by conventional imaging in patients with locally advanced breast cancer , 2013, Nuclear medicine communications.

[15]  A. Alavi,et al.  Degree of Tumor FDG Uptake Correlates with Proliferation Index in Triple Negative Breast Cancer , 2010, Molecular Imaging and Biology.

[16]  D. Mankoff,et al.  Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer , 2011, Clinical Cancer Research.

[17]  D. Mankoff,et al.  Between-Patient and Within-Patient (Site-to-Site) Variability in Estrogen Receptor Binding, Measured In Vivo by 18F-Fluoroestradiol PET , 2011, The Journal of Nuclear Medicine.

[18]  T. Sharp,et al.  Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies. , 2008, Nuclear medicine and biology.

[19]  J. Jacob,et al.  Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3´-deoxy-3´-fluorothymidine PET: a pilot study. , 2012, Biomarkers in medicine.

[20]  H. J. Son,et al.  Additional value of F-18 FDG PET/CT for initial staging in breast cancer with clinically negative axillary nodes , 2014, Breast Cancer Research and Treatment.

[21]  W. Shi,et al.  Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo? , 2013, Clinical breast cancer.

[22]  Young Ha Park,et al.  Value of F-18 FDG PET/CT in detection and prognostication of isolated extra-axillary lymph node recurrences in postoperative breast cancer. , 2014, Bio-medical materials and engineering.

[23]  D. Groheux,et al.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  R. Reilly,et al.  Trastuzumab Labeled to High Specific Activity with 111In by Conjugation to G4 PAMAM Dendrimers Derivatized with Multiple DTPA Chelators Exhibits Increased Cytotoxic Potency on HER2-Positive Breast Cancer Cells , 2013, Pharmaceutical Research.

[25]  W. Yang.  18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) Imaging in the Staging and Prognosis of Inflammatory Breast Cancer , 2010 .

[26]  Evaluating heterogeneity of primary tumor 18F-FDG uptake in breast cancer with a dedicated breast PET (MAMMI): a feasibility study based on correlation with PET/CT , 2014, Nuclear medicine communications.

[27]  A. Alavi,et al.  Comparison of triple‐negative and estrogen receptor‐positive/progesterone receptor‐positive/HER2‐negative breast carcinoma using quantitative fluorine‐18 fluorodeoxyglucose/positron emission tomography imaging parameters , 2008, Cancer.

[28]  Alessandro Giordano,et al.  Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis. , 2014, Clinical breast cancer.

[29]  D. Mankoff,et al.  Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients , 2012, EJNMMI Research.

[30]  C. Hong,et al.  Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer , 2011, Nuclear medicine and molecular imaging.

[31]  V. Edeline,et al.  18F-FDG PET/CT imaging versus dynamic contrast-enhanced CT for staging and prognosis of inflammatory breast cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  V. Seshan,et al.  Feasibility and Predictability of Perioperative PET and Estrogen Receptor Ligand in Patients with Invasive Breast Cancer , 2013, The Journal of Nuclear Medicine.

[33]  O. Olopade,et al.  Molecular subtypes of breast cancer , 2014 .

[34]  A. Jemal,et al.  Breast Cancer Statistics , 2013 .

[35]  T. Lemarchand-Béraud,et al.  The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women °clinical correlation on 547 patients , 1986, Cancer.

[36]  P. Marsden,et al.  Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. , 2012, European journal of cancer.

[37]  J E Mortimer,et al.  Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  The Effect of Metal-Chelating Polymers (MCPs) for 111In Complexed via the Streptavidin-Biotin System to Trastuzumab Fab Fragments on Tumor and Normal Tissue Distribution in Mice , 2012, Pharmaceutical Research.

[39]  Fat necrosis may mimic local recurrence of breast cancer in FDG PET/CT. , 2013, Revista espanola de medicina nuclear e imagen molecular.

[40]  Federico Turkheimer,et al.  [18F]-3′Deoxy-3′-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel , 2011, Clinical Cancer Research.

[41]  J. García-Saenz,et al.  18F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: association of loco‑regional SUVmax with classical prognostic factors. , 2014, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[42]  D. Mankoff,et al.  Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. , 2011, Nuclear medicine and biology.

[43]  D. Groheux,et al.  Performance of FDG PET/CT in the clinical management of breast cancer. , 2013, Radiology.

[44]  E. Rutgers,et al.  The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[45]  Vered Stearns,et al.  Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[47]  P. Chow,et al.  2-[18f]-2-deoxy-d-glucose (fdg) uptake in human tumor cells is related to the expression of glut-1 and hexokinase ii , 2008, Acta radiologica.

[48]  E. D. de Vries,et al.  Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  S. Rodenhuis,et al.  Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II–III breast cancer patients treated with neoadjuvant chemotherapy , 2013, Breast Cancer Research and Treatment.

[50]  J. Bading,et al.  Functional Imaging of Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET , 2014, The Journal of Nuclear Medicine.

[51]  W. Eubank,et al.  Diagnosis of recurrent and metastatic disease using f-18 fluorodeoxyglucose-positron emission tomography in breast cancer. , 2007, Radiologic clinics of North America.

[52]  J. Manson,et al.  Prospective Study of , 2007 .

[53]  Xu Cheng,et al.  18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis , 2012, Acta radiologica.

[54]  C. Geyer,et al.  Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma , 2005, Cancer.

[55]  J. Youk,et al.  The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer , 2010, Acta radiologica.

[56]  Van der Leij,et al.  Optimizing treatment of low risk breast cancer patients , 2017 .

[57]  M. Mintun,et al.  Positron Tomographic Assessment of 16α-[18F] Fluoro-17β-Estradiol Uptake in Metastatic Breast Carcinoma , 1991 .

[58]  D. Mankoff,et al.  Evaluation of the Internal Mammary Lymph Nodes by FDG-PET in Locally Advanced Breast Cancer (LABC) , 2004, American journal of clinical oncology.

[59]  S. Rodenhuis,et al.  FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. , 2013, Breast.

[60]  T. Fujii,et al.  Early predictive value of non-response to docetaxel in neoadjuvant chemotherapy in breast cancer using 18F-FDG-PET. , 2014, Anticancer Research.

[61]  M. Schwaiger,et al.  Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[62]  K. Nakagawa,et al.  Early distant relapse in early stage triple-negative breast cancer: usefulness of FDG-PET for diagnosis of distant metastases , 2013, Breast Cancer.

[63]  Won Hwa Kim,et al.  18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes , 2014, European Radiology.

[64]  Paul J. van Diest,et al.  Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .

[65]  B. Kim,et al.  Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer , 2012, Annals of Nuclear Medicine.

[66]  F. O'Malley,et al.  Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  J. Vercher-Conejero,et al.  Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers. , 2013, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[68]  W. Yang,et al.  False-positive lesions mimicking breast cancer on FDG PET and PET/CT. , 2012, AJR. American journal of roentgenology.

[69]  M. Campone,et al.  FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[70]  A. Ozet,et al.  Abnormal 18F-FDG Uptake Detected with Positron Emission Tomography in a Patient with Breast Cancer: A Case of Sarcoidosis and Review of the Literature , 2009, Case reports in medicine.

[71]  Michael Rugaard Jensen,et al.  (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. , 2010, European journal of cancer.

[72]  A. Bhattacharya,et al.  F-18 fluoro-deoxy-glucose and F-18 sodium fluoride cocktail PET/CT scan in patients with breast cancer having equivocal bone SPECT/CT , 2014, Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India.

[73]  M. Mesiti,et al.  Do multiple oestrogen receptor assays give significant additional information for the management of breast cancer? , 1989, British Journal of Cancer.

[74]  Zhongyi Yang,et al.  Increased 18F-fluoroestradiol uptake in radiation pneumonia , 2013, Annals of Nuclear Medicine.

[75]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[76]  S. Shousha,et al.  Reproducibility of [11C]Choline-Positron Emission Tomography and Effect of Trastuzumab , 2010, Clinical Cancer Research.

[77]  Jingyi Cheng,et al.  Can Positron Emission Tomography/Computed Tomography with the Dual Tracers Fluorine-18 Fluoroestradiol and Fluorodeoxyglucose Predict Neoadjuvant Chemotherapy Response of Breast Cancer? ----A Pilot Study , 2013, PloS one.

[78]  J. O,et al.  The Prognostic Value of 18F-FDG PET/CT for Early Recurrence in Operable Breast Cancer: Comparison with TNM Stage , 2013, Nuclear Medicine and Molecular Imaging.

[79]  A. Jena,et al.  imultaneous whole-body 18 F-FDG PET-MRI in primary staging of reast cancer : A pilot study , 2014 .

[80]  M. Reza,et al.  A systematic review of FDG-PET in breast cancer , 2010, Medical oncology.

[81]  S. Shousha,et al.  [11C]Choline Positron Emission Tomography in Estrogen Receptor–Positive Breast Cancer , 2009, Clinical Cancer Research.

[82]  M. Leach,et al.  MRI breast screening in high-risk women: cancer detection and survival analysis , 2014, Breast Cancer Research and Treatment.

[83]  C. Pirich,et al.  FDG PET/CT for monitoring response to neoadjuvant chemotherapy in breast cancer patients , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[84]  M. Schwaiger,et al.  Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer , 2009, British Journal of Cancer.

[85]  D. Mankoff,et al.  Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  Jason S. Lewis,et al.  H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu. , 2014, Dalton transactions.

[87]  J. Heverhagen,et al.  Comparison of gadobenate dimeglumine‐enhanced breast MRI and gadopentetate dimeglumine‐enhanced breast MRI with mammography and ultrasound for the detection of breast cancer , 2014, Journal of Magnetic Resonance Imaging.

[88]  Q. Chu,et al.  The Role of Whole-Body Fluorine-18-FDG Positron Emission Tomography in the Detection of Recurrence in Symptomatic Patients with Stages II and III Breast Cancer , 2006, World Journal of Surgery.

[89]  A. d’Amico,et al.  Paradoxal metabolic flare detected by 18F-fluorodeoxyglucose positron emission tomography in a patient with metastatic breast cancer treated with aromatase inhibitor and biphosphonate , 2014, Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India.

[90]  Thomas J. Smith,et al.  Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  Kyung-Han Lee,et al.  17β-Estradiol Augments 18F-FDG Uptake and Glycolysis of T47D Breast Cancer Cells via Membrane-Initiated Rapid PI3K–Akt Activation , 2010, The Journal of Nuclear Medicine.

[92]  A. Jemal,et al.  Breast cancer statistics, 2013 , 2014, CA: a cancer journal for clinicians.

[93]  C. Coutant,et al.  18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[94]  D. Groheux,et al.  ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. , 2014, European journal of radiology.

[95]  H. Kato,et al.  Utility of FDG-PET/CT in the evaluation of the response of locally advanced breast cancer to neoadjuvant chemotherapy. , 2014, International surgery.

[96]  N. Avril.  Metabolic FDG-PET imaging in breast cancer: implications for treatment stratification , 2007, Nature Clinical Practice Oncology.

[97]  M. Brigden,et al.  Cellular distribution patterns of estrogen receptor in human breast cancer. , 1988, European journal of cancer & clinical oncology.

[98]  R. Avery,et al.  18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound. , 2013, Clinical nuclear medicine.

[99]  M. Welch,et al.  Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[100]  Eric O. Aboagye,et al.  Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[101]  C. Caldwell,et al.  Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments. , 2013, Nuclear medicine and biology.

[102]  M. Mintun,et al.  Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[103]  Hiroshi Honda,et al.  Diagnostic and Prognostic Value of Pretreatment SUV in 18F-FDG/PET in Breast Cancer: Comparison with Apparent Diffusion Coefficient from Diffusion-Weighted MR Imaging , 2014, The Journal of Nuclear Medicine.

[104]  M. Sasaki,et al.  Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma , 2003, Annals of nuclear medicine.

[105]  D. Noh,et al.  Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer , 2001, World Journal of Surgery.

[106]  M. Hou,et al.  Bone metastasis versus bone marrow metastasis? Integration of diagnosis by 18F‐fluorodeoxyglucose positron emission/computed tomography in advanced malignancy with super bone scan: Two case reports and literature review , 2013, The Kaohsiung journal of medical sciences.

[107]  K. Tonkin,et al.  Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients. , 2007, Journal of Pharmacy & Pharmaceutical Sciences.

[108]  F Sanchez,et al.  Design and evaluation of the MAMMI dedicated breast PET. , 2012, Medical physics.

[109]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[110]  D. Groheux,et al.  18F-FDG PET/CT in Staging Patients with Locally Advanced or Inflammatory Breast Cancer: Comparison to Conventional Staging , 2013, The Journal of Nuclear Medicine.

[111]  P. L. Jager,et al.  Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.

[112]  P. V. van Diest,et al.  Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.